| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
Over the past 90 days, insiders at Nurix Therapeutics, Inc. (NRIX) have been net sellers, shedding 49,260 shares worth roughly $1.2M on balance. In the past 30 days, 0 insiders bought and 4 sold.
All 4 insiders who sold still hold shares after their sales.
| Role | Insider | Shares | Value | 30d |
|---|---|---|---|---|
| Other | 123.5K | $3.19M | -6,861 | |
| CFO | 47.5K | $1.23M | -2,834 | |
| Other | 15.3K | $395.9K | -3,957 | |
| Dir | 10.8K | $277.6K | -22,583 |
Buys and sells only
| Date | Insider | Role | Type | Shares | Price | Value | Chg% | 3M | 12M | SEC |
|---|---|---|---|---|---|---|---|---|---|---|
| Jan 30, 2024 | Gwenn Hansen70 | Chief Scientific Officer | Sale+OE | 2,334 | $7.99 | $18,649.13 | -6.0% | +56.1% | +145.9% | |
| Jan 30, 2024 | Christine Ring75 | Chief Legal Officer | Sale+OE | 1,760 | $7.99 | $14,062.75 | -9.2% | +56.1% | +145.9% | |
| Jan 30, 2024 | Hans van Houte56 | Chief Financial Officer | Sale+OE | 1,671 | $7.99 | $13,351.62 | -2.2% | +56.1% | +145.9% | |
| Dec 20, 2023 | Hans van Houte56 | Chief Financial Officer | Sell10b5-1 | 3,541 | $10.00 | $35,420.98 | -4.7% | +29.6% | +103.9% | |
| Dec 19, 2023 | Hans van Houte56 | Chief Financial Officer | Sell10b5-1 | 10,906 | $10.00 | $109,092.72 | -12.6% | +29.3% | +103.8% | |
| Oct 31, 2023 | Christine Ring75 | Chief Legal Officer | Sale+OE | 1,232 | $5.20 | $6,403.20 | -7.5% | +49.7% | +330.6% | |
| Oct 31, 2023 | Gwenn Hansen70 | Chief Scientific Officer | Sale+OE | 1,633 | $5.20 | $8,487.35 | -4.6% | +49.7% | +330.6% | |
| Oct 31, 2023 | Hans van Houte56 | Chief Financial Officer | Sale+OE | 1,080 | $5.20 | $5,613.19 | -1.2% | +49.7% | +330.6% | |
| Jul 31, 2023 | Hans van Houte56 | Chief Financial Officer | Sale+OE | 1,245 | $9.65 | $12,020.10 | -1.5% | -45.8% | +113.9% | |
| Jul 31, 2023 | Christine Ring75 | General Counsel | Sale+OE | 1,420 | $9.65 | $13,709.67 | -10.2% | -45.8% | +113.9% |